Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.
At a major transplant center in Indiana, despite similar levels of liver disease severity, Blacks had a lower transplant rate than whites.
Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.
Hepatitis B patients who used aspirin therapy had a 37 percent lower rate of hepatocellular carcinoma.
One of the major international conferences on all aspects of liver disease, opened Sunday in Washington, DC.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.